Live Chat

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

VirBiotechnology live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Info

Spread

0.05

Spread (%)

0.6562 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1317845888

Shares Outstanding

136706000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.58

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments

Latest news

Stay updated with the latest financial news from around the world.

Wednesday, 6 November 2024

U.S. presidential election market volatility drives Bitcoin prices to reach a historic high

Stock market rally

Tuesday, 5 November 2024

US Election Results Trigger Stock Gains Across Europe, Asia, and US

US Election Trump's victory

Tuesday, 5 November 2024

Trump Victory Spurs Market Gains and Economic Shift Expectations

Tuesday, 5 November 2024

US election: bitcoin price (BTC) surged to new record as Trump leading ahead

Tuesday, 5 November 2024

Stock Market Today: Wall Street Rallies on Election Day Amid Strong Economic Outlook

US Election 2024 Trump

Tuesday, 5 November 2024

Early Election Results Shift Markets as Trump’s Chances Rise

Monday, 4 November 2024

Stock Market Today: S&P 500 Declines as Investors Brace for US Election

Monday, 4 November 2024

US election: What will happen to tesla stock if Trump wins?

Trustpilot
Live Chat